Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
 EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Volume 9, Number 6, June 2003

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi

Stephen B. Gordon,* Stonard Kanyanda,* Amanda L. Walsh,* Kristy Goddard,* Mas Chaponda,† Victoria Atkinson,† Wakisa Mulwafu,† Elizabeth M. Molyneux,† Ed E. Zijlstra,† Malcolm E. Molyneux,* and Steve M. Graham*
*Wellcome Trust Research Laboratories, University of Malawi, Liverpool, U.K.; and †University of Malawi College of Medicine, Blantyre, Malawi

 
 
Figure.
  Back to article
 

Figure. The cumulative percentage of all pneumococcal isolates plotted by source (see key). Serogroups covered by the 7-valent vaccine are plotted to the left of the heavy vertical line, and the potential 9-valent coverage is illustrated by the dotted vertical line.

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed May 13, 2003

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention